Interferon beta-1 (IFN-β) (IFN-β)

Interferon beta-1 (IFN-β) is a type I interferon cytokine that plays a pivotal role in the innate immune response, particularly within hepatic cells during viral infections. It is produced by hepatocytes and resident immune cells in response to the detection of viral nucleic acids by pattern recognition receptors like RIG-I and TLR3 (UniProt P01574). Once produced, IFN-β acts in an autocrine or paracrine fashion by binding to the Interferon-alpha/beta receptor (IFNAR) complex, which consists of IFNAR1 and IFNAR2 subunits (PubMed: 28278486). This binding triggers the JAK-STAT signaling pathway, leading to the nuclear translocation of the ISGF3 complex and the subsequent transcription of hundreds of interferon-stimulated genes (ISGs) that establish an antiviral state and modulate immune cell recruitment (PubMed: 30107249). Clinically, recombinant forms of IFN-β, such as interferon beta-1a and beta-1b, are primarily used to treat multiple sclerosis, but the pathway remains a significant focus for research into chronic hepatitis B and C and hepatocellular carcinoma (DrugBank DB00060). However, therapeutic use is often limited by systemic side effects, including flu-like symptoms and potential hepatotoxicity, necessitating careful monitoring of liver function (PubMed: 21455605).

Other names

IFNB1IFN-betaFibroblast interferonInterferon beta-1aInterferon beta-1b

Agonism of the heterodimeric Interferon-alpha/beta receptor (IFNAR) complex, which activates the JAK-STAT signaling pathway (specifically JAK1 and TYK2), leading to the formation of the ISGF3 transcription factor complex and the induction of interferon-stimulated genes (ISGs).